Changeflow GovPing Healthcare & Life Sciences Predicting Cell Differentiation Using HICA Content
Routine Notice Added Final

Predicting Cell Differentiation Using HICA Content

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO has published application US20260109921A1, filed November 8, 2022 by inventors Shiori NAKAZAWA, Midori KATO, Hikaru SAITO, Hiroko HANZAWA, and Shizu TAKEDA. The invention discloses a non-invasive method for predicting the differentiation level of cultured cells by measuring HICA content in culture supernatant collected after differentiation induction begins but before it ends, then inputting the measurement into a prediction model. The method may be implemented using a prediction device and aims to enable early-stage differentiation assessment without destructive testing.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 263 changes logged to date.

What changed

The USPTO published patent application US20260109921A1 covering a method and device for predicting cell differentiation levels using HICA (alpha-hydroxyisocaproic acid) content measurements in culture supernatant. The method involves three steps: collecting culture supernatant after differentiation induction starts but before it ends, measuring HICA content in that supernatant, and inputting the HICA measurement into a prediction model to generate a differentiation level prediction. CPC classifications indicate applications in cell culture apparatus (C12M) and cell/tissue culture technologies (C12N).

Parties interested in cell culture-based bioprocessing, regenerative medicine research, or related biotechnology development should note this publication for prior art purposes. The application establishes an early priority date of November 8, 2022 and may affect freedom-to-operate analyses for similar non-invasive cell monitoring approaches.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PREDICTION METHOD AND PREDICTION DEVICE

Application US20260109921A1 Kind: A1 Apr 23, 2026

Inventors

Shiori NAKAZAWA, Midori KATO, Hikaru SAITO, Hiroko HANZAWA, Shizu TAKEDA

Abstract

Prediction of a differentiation level of a cultured cell is performed non-invasively and simply in an early stage from the end of differentiation induction. A prediction method includes collecting the culture supernatant of the prediction target cultured cell after the start of differentiation induction and before the end of differentiation induction, measuring the content of HICA in the culture supernatant of the collected prediction target cultured cell (step S22), and inputting the content of HICA in the culture supernatant of the prediction target cultured cell measured in the prediction model to predict a differentiation level of the prediction target cultured cell (step S23).

CPC Classifications

C12M 1/343 C12M 3/00 C12N 5/0696 C12N 2506/45

Filing Date

2022-11-08

Application No.

19118254

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies Clinical investigators
Industry sector
3254.1 Biotechnology
Activity scope
Patent application Biotechnology research Cell culture technology
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!